Matthew R. Kane
Net Worth

Last updated:

What is Matthew R. Kane net worth?

The estimated net worth of Mr. Matthew R. Kane is at least $14,958,370 as of 13 May 2021. He owns shares worth $9,665,266 as insider, has earned $891,924 from insider trading and has received compensation worth at least $4,401,180 in Precision BioSciences, Inc..

What is the salary of Matthew R. Kane?

Mr. Matthew R. Kane salary is $733,530 per year as Advisor in Precision BioSciences, Inc..

How old is Matthew R. Kane?

Mr. Matthew R. Kane is 48 years old, born in 1977.

What stocks does Matthew R. Kane currently own?

As insider, Mr. Matthew R. Kane owns shares in one company:

Company Title Shares Price per share Total value
Precision BioSciences, Inc. (DTIL) Advisor 2,013,597 $4.8 $9,665,266

What does Precision BioSciences, Inc. do?

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL logo
DTIL
Precision BioSciences, Inc.
$4.8

Matthew R. Kane insider trading

Precision BioSciences, Inc.

Mr. Matthew R. Kane has made 15 insider trades between 2019-2021, according to the Form 4 filled with the SEC. Most recently he sold 9,675 units of DTIL stock on 13 May 2021.

The largest trade he's ever made was exercising 21,515 units of DTIL stock on 26 Jan 2021. As of 13 May 2021 he still owns at least 2,013,597 units of DTIL stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 9,675 N/A N/A
Option
Employee Stock Option (Right to Buy) 21,514 N/A N/A
Option
Common Stock 21,514 N/A N/A
Option
Common Stock 21,514 $0.04 $861
Option
Employee Stock Option (Right to Buy) 21,514 $0.04 $861
Sale
Common Stock 9,746 $8.25 $80,405
Sale
Common Stock 9,742 $8.57 $83,489
Option
Employee Stock Option (Right to Buy) 21,514 $0.04 $861
Option
Common Stock 21,514 $0.04 $861
Option
Common Stock 13,422 N/A N/A
Option
Employee Stock Option (Right to Buy) 13,422 N/A N/A
Option
Common Stock 21,514 $0.04 $861
Option
Employee Stock Option (Right to Buy) 21,514 N/A N/A
Sale
Common Stock 9,741 N/A N/A
Sale
Common Stock 9,737 N/A N/A
Option
Employee Stock Option (Right to Buy) 21,514 $0.04 $861
Option
Common Stock 21,514 $0.04 $861
Sale
Common Stock 9,736 $9 $87,624
Option
Employee Stock Option (Right to Buy) 21,514 N/A N/A
Option
Common Stock 21,514 $0.04 $861
Sale
Common Stock 9,712 $11.36 $110,328
Option
Employee Stock Option (Right to Buy) 21,514 $0.04 $861
Option
Common Stock 21,514 $0.04 $861
Sale
Common Stock 9,711 N/A N/A
Option
Employee Stock Option (Right to Buy) 21,514 $0.04 $861
Option
Common Stock 21,514 N/A N/A
Sale
Common Stock 9,710 N/A N/A
Option
Common Stock 21,514 N/A N/A
Option
Employee Stock Option (Right to Buy) 21,514 N/A N/A
Option
Employee Stock Option (Right to Buy) 21,514 N/A N/A
Option
Common Stock 21,514 N/A N/A
Sale
Common Stock 9,705 N/A N/A
Option
Common Stock 21,514 N/A N/A
Sale
Common Stock 9,705 N/A N/A
Option
Employee Stock Option (Right to Buy) 21,514 N/A N/A
Sale
Common Stock 9,697 $13.3 $128,970
Option
Common Stock 21,514 N/A N/A
Option
Employee Stock Option (Right to Buy) 21,514 N/A N/A
Option
Employee Stock Option (Right to Buy) 21,515 $0.04 $861
Sale
Common Stock 9,697 $13.37 $129,649
Option
Common Stock 21,515 $0.04 $861
Sale
Common Stock 9,695 $13.74 $133,209
Option
Common Stock 21,514 $0.04 $861
Option
Employee Stock Option (Right to Buy) 21,514 N/A N/A
Sale
Common Stock 10,218 $13.53 $138,250
Option
Employee Stock Option (Right to Buy) 21,514 $0.04 $861
Option
Common Stock 21,514 $0.04 $861
Option
Employee Stock Option (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A

Precision BioSciences key executives

Precision BioSciences, Inc. executives and other stock owners filed with the SEC: